PRNewswire

Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially disease-mod

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: